

M. A. Topçuoğlu  
R. Karabudak

## Familial Mediterranean fever and multiple sclerosis

Received: 2 September 1996  
Received in revised form:  
31 December 1996  
Accepted: 6 May 1997

Presented at the Sixth Meeting  
of the European Neurological Society,  
The Hague, The Netherlands,  
8–12 June 1996

M. A. Topçuoğlu · R. Karabudak (✉)  
Department of Neurology,  
Hacettepe University Hospitals,  
TR-06100 Ankara, Turkey  
Tel.: 90-312-3104197  
Fax: 90-312-309 3451  
e-mail: rk01-k@servis.net.tr

**Abstract** Central nervous system (CNS) manifestations of familial Mediterranean fever (FMF) are extremely rare. These include pseudo-tumor cerebri, optic neuritis, CNS complications of polyarteritis nodosa type vasculitis, or hypercoagulable states secondary to renal amyloidosis, recurrent aseptic meningitis, and amyloid ophthalmoplegia. We present three patients with FMF whose neurological findings and magnetic resonance imaging (MRI) abnormalities resembled multiple sclerosis (MS). These two conditions in the

same patient could arise from either coincidence or an unknown pathophysiological relationship. Both explanations are equally speculative and this matter needs further study, especially to investigate MRI features in FMF patients without CNS symptoms.

**Key words** Familial Mediterranean fever · Neurological complications · Multiple sclerosis

### Introduction

Familial Mediterranean fever (FMF) is an inherited disorder affecting several ethnic groups in the Middle East and in Mediterranean countries. FMF, also known as periodic disease or recurrent polyserositis, is an autosomal recessive disorder characterized by recurrent attacks of fever, synovitis, peritonitis, or pleuritis. Less frequent manifestations include skin rash, myalgia and systemic amyloidosis [6, 18]. The cause of the disease is unknown. Recent genetic studies have shown that the gene for FMF is located on chromosome 16p [22, 25]. The diagnosis of FMF is usually made on clinical grounds, typically when recurrent attacks of abdominal pain, fever, and arthritis are observed in a patient with an appropriate ethnic background and family history [3]. So far, there is no specific diagnostic laboratory test for FMF [6].

Central nervous system (CNS) manifestations of FMF are very rare and remain controversial. We describe a previously unreported association of FMF and multiple sclerosis (or multiple sclerosis-like syndrome [8, 23]).


### Case reports

*Patient 1* was a 34-year-old man who had been admitted 3 years previously because of a 1-month history of numbness and hypaesthesia on the lower extremities. He had been followed up with the diagnosis of FMF for 23 years and had used colchicine (1.5 mg/day) during that time (Table 1). Neurological examination did not reveal any abnormalities except for hypaesthesia below the T10 level. Cranial MRI showed multiple hyperintense lesions in the deep and periventricular white matter on the T2 weighted images (Fig. 1). MRI of the spinal cord was normal. CSF investigations, including a search for protein and oligoclonal bands were normal. A visual evoked potential (VEP) study showed normal P100 latency and amplitude. Brain-stem auditory evoked responses (BAER) and somatosensory evoked potential (SEP) were abnormal. Other laboratory tests showed normal values (Table 2). A diagnosis of non-compressive cord syndrome was suggested and treatment with methyl-prednisolone was given. Repeated brain MRI showed considerable resolution in the size and number of the lesions, and the SEP study became normal. The neurological findings did not change. He had been well during follow-up for 3 years. However, 3.5 years later he was evaluated for painless right monocular visual loss, which developed over a few days. On examination, the visual acuity in his right eye was reduced to 20/800 with decreased red colour perception and a right relative afferent pupillary defect. No optic disk pallor was present on ophthalmoscopic examination. Visual field examination disclosed a moderate

**Table 1** Clinical data

| Patient | Age (years) | Sex    | Age at diagnosis of FMF (years) | Age at the beginning of symptoms ascribed to MS | Time interval (years) | Family history   |
|---------|-------------|--------|---------------------------------|---|-----------------------|------------------|
| 1       | 30          | Female | 18                              | 30  | 12                    | (+) <sup>a</sup> |
| 2       | 25          | Male   | 20                              | 24  | 4                     | (-)              |
| 3       | 34          | Male   | 23                              | 34  | 11                    | (-)              |

<sup>a</sup> FMF were diagnosed in two of four siblings; one of them also had PAN like vasculitis



**Fig. 1** Sagittal (A) and axial (B) T2-weighted MRI of the brain in patient 1 showing multiple hyperintense signal changes in the periventricular white matter

**Fig. 2** Transversal T1 (A) and T2 (B)-weighted MRI of the brain in patient 2 showing multiple white matter lesions consistent with demyelinating plaques

right visual field constriction, beginning with a superior altitudinal defect. His physical and neurological examinations were otherwise unremarkable. Routine blood tests including serological tests for syphilis and brucellosis were normal. P100 wave latency, on pattern reversal VEP study, was prolonged over the right eye. His repeated MRI showed no significant changes compared with the previous one. A demyelinating optic neuritis was considered and he was given methylprednisolone therapy. Over a 3-week period the patient's visual acuity gradually returned to normal. No cases of optic neuritis were reported in the family.

*Patient 2* was a 30-year-old female with 3-month history of gait difficulty, diplopia, fatigue, and depression. She had mild gait ataxia, titubation, up-beat nystagmus, bilateral Babinski sign, and a bilateral moderate intention tremor on neurological examination. Age at diagnosis of FMF was 18 years. Since then, she had been given colchicine therapy (0.5 mg/day) and the abdominal pain attacks were well controlled. FMF was diagnosed in two of her four siblings. Her brother had also PAN-like vasculitis. As shown in Table 2, laboratory tests showed high ESR and fibrinogen level. The markers of collagen tissue disorder were normal except for nonspecific and slightly high titre of ANA. Multimodal evoked potential studies were abnormal, and CSF IgG index was high. A diagnosis of demyelinating disease on the basis of brain MRI findings suggestive of MS (Fig. 2) was considered and treatment with methyl-prednisolone was given. A slight improvement in gait ataxia was noted at the end of the therapy.

*Patient 3* was a 25-year-old male. Acute monoparesis of the left lower extremity which resolved spontaneously within 2 weeks had been documented in another neurology centre 3 years previ-

**Table 2** Results of laboratory testing

|   | Patient 1             | Patient 2        | Patient 3         |
|---|-----------------------|------------------|-------------------|
| <b>Haematological and urinary</b>             |                       |                  |                   |
| Erythrocyte sedimentation rate (ESR; mm/h)    | 24                    | 85               | 100               |
| BUN/Cre                                       | 12/0.9                | 8/0.52           | 11/1.2            |
| Urine protein (mg/l)                          | (-)                   | (-)              | 200               |
| Creatinin clearance (ml/min)                  | 120                   | ?                | 148               |
| Serum albumin/protein                         | 3.9/6.9               | 4.2/7.4          | 2.6/4.6           |
| <b>Cerebrospinal fluid</b>                    |                       |                  |                   |
| Cells   | 5 RBC/mm <sup>3</sup> | (-)              | (-)               |
| Glucose (mg/dl)                               | 64                    | 56               | 56                |
| Protein (mg/dl)                               | 40                    | 42               | 22                |
| Ig G Index                                    | 0.4 <sup>a</sup>      | 2.6 <sup>a</sup> | 1.98 <sup>a</sup> |
| Oligoclonal band                              | (-)                   | (-)              | (+)               |
| <b>Immunological and Serological</b>          |                       |                  |                   |
| Anti-nuclear antigen                          | (-) <sup>c</sup>      | (+) <sup>b</sup> | (-)               |
| Anti-double-stranded DNA (IU/ml)              | 1.2                   | 5.2              | 0.2               |
| Rheumatoid factor                             | (-) <sup>c</sup>      | (-)              | (-)               |
| Anti-cardiolipin antibodies (IgG/IgM)         | (-) <sup>c</sup>      | (-/-)            | (-/-)             |
| Antineutrophil cytoplasmic antibodies (c-/p-) | (-) <sup>c</sup>      | (-/-)            | (-/-)             |
| VDRL  | (-)                   | (-)              | (-)               |
| Brucella antigen                              | (-)                   | (-)              | (-)               |
| Fibrinogen (mg/dl)                            | 390                   | 580              | 521               |
| <b>Electrophysiologic</b>                     |                       |                  |                   |
| VEP   | Normal <sup>d</sup>   | Abnormal         | Abnormal          |
| SEP   | Abnormal              | Abnormal         | Abnormal          |
| BAEP  | Abnormal              | Abnormal         | Abnormal          |

<sup>a</sup>Reference value: 0.2–0.5

<sup>b</sup>1/40 titre and speckled pattern

<sup>c</sup>Obtained in second attack

<sup>d</sup>Abnormal in second attack


ously. He had been treated with 1.5 mg daily colchicine with the diagnosis of FMF for 5 years. He also had proteinuria due to renal amyloidosis, which was proven by biopsy. Two years later he was admitted to our hospital because of acute paraparesis. MRI of brain and spinal cord revealed multiple lesions compatible with MS (Fig. 3). The results of laboratory tests are summarized in Table 2. No therapy was recommended except continuation of colchicine because of spontaneous complete recovery of the symptoms.

## Discussion

FMF is rarely complicated by neurological symptoms. Pathological findings are those of a non-specific acute inflammation. Amyloid may be deposited in intima and media of the arterioles and in the subendothelium of venules in all major organs. Liver, heart and brain are believed to be characteristically spared. In the literature, there have been reports of pseudotumor cerebri [7], optic neuritis [13], CNS complications of polyarteritis nodosa type vasculitis [9], or hypercoagulable states secondary to renal amyloidosis [26], headaches, nonspecific electroencephalographic changes during attack [13], recurrent aseptic meningitis [1, 24], ischaemic stroke due to coincidental reasons [27] and amyloid ophthalmoplegia [12] among the spectrum of neurological involvement in patients with FMF. However, FMF has not previously been reported in association with MS.

The association between FMF and MS may arise from a simple co-occurrence. This seems highly speculative because of the low incidence of these disorders in the Turkish population; nevertheless, we cannot rule out this possibility. The first and the third patients had two separate attacks. According to Poser's criteria [21] the first and third patients could be classified as clinically definite MS, while the second patient had laboratory supported definite MS. Establishing these diagnoses requires exclusion of other diseases by appropriate tests. Moreover, multifocal white matter lesions as seen in T2 weighted MRI are known to be not unique to MS [5]. A variety of neurological conditions can cause white matter abnormalities, but this has not been documented for FMF to date. Most of the conditions resulting with MRI white matter abnormalities, especially neurosarcoidosis, Behcet's syndrome, Sjögren syndrome, polyarteritis nodosa, ADEM, SLE and ageing, can be ruled out by age, clinical and laboratory features. Behcet's syndrome, which is more prevalent in Turkey, was easily excluded with the absence of any of the major diagnostic criteria including oral aphthous ulcers, genital ulcerations, typical eye or skin lesions, and positive pathergy test [11].

The serological tests for syphilis and brucellosis were performed, but not for Lyme disease, which is extremely rare in Turkey. We know CT and MRI display multifocal and periventricular cerebral lesions in the chronic phase



**Fig. 3** Axial T2-weighted MRI images of the brain and spinal cord in patient 3 reveal multiple hyperintense lesions in periventricular white matter (A), in brachium pontis (B) and in medulla spinalis (C)

of Lyme disease [4]. However, none of the presented cases had the usual pattern of systemic or neurological involvement of Lyme disease. Neither meningoencephalitis, cranial or peripheral neuritis, radiculitis as the most common neurological manifestations nor systemic symptoms and skin lesions as systemic involvement were observed. There was no mild lymphocytosis or mild elevation of protein levels in the CSF.

FMF is not a systemic vasculitic disease. However, PAN-like vasculitis may rarely develop [9]. The diagnosis of this type of vasculitis remains largely dependent on visceral angiography and peripheral nerve biopsy. On the basis of the absence of the distinctive clinical and serological features of PAN, this possibility could be excluded [10, 19].

Colchicine-induced neurotoxicities causing vitamin B<sub>12</sub> deficiency have been reported [20]. None of the patients presented here had low B<sub>12</sub> levels and there has been no colchicine-associated optic neuritis or MS reported in the literature. However, the direct toxic effect of colchicine is not excluded. It has not been described before, but colchicine has never been used before on a young population continuously for many years, and our knowledge of its mode of action and long-term effects is limited.

The “decreased anti-inflammatory response” hypothesis [3, 14–17] and other putative mechanisms such as FMF-associated chronic antigenaemia, oxygen radical-mediated chromosome damage, or FMF-related immunological mechanism including relative bone marrow plasmacytosis, T-cell dysfunctions, and lymphocytotoxins [2, 6, 16] may all be relevant, but inadequate explain the exact pathophysiology of this disease. Whether or not the underlying mechanism is immunologically mediated and whether CNS involvement takes place in FMF owing to those inflammatory changes may be revealed by further experience.

All the mechanisms proposed above remain speculative. A study designed to investigate MRI features in FMF patients without CNS symptoms is necessary to understand the nature of MRI appearances in FMF. This seems to be the only way to learn whether the observed MRI lesions are related to FMF or to MS.

All of the presented patients had already been treated with colchicine (0.5–1.5 mg/day) at the time of commencement of CNS-related symptoms. We continued with this therapy and added intravenous methyl prednisolone in two patients, and a slight improvement was noted in one. If we consider the two diseases as two different entities without any pathophysiological relationship, colchicine alone seems ineffective in the treatment of neurological disease and corticosteroids are recommended.

## References

1. Barakat MH, Mustafa HT, Shakir RA (1988) Mollaret's meningitis: a variant of recurrent hereditary polyserositis, both provoked by metaraminol. *Arch Neurol* 45:926-927
2. Cook GC (1986) Periodic disease, recurrent polyserositis, familial Mediterranean fever, or simply FMF. *Q J Med* 60:819-823
3. Cook GC (1996) Familial Mediterranean fever: underlying defect clearer, but diagnostic problems persist. *Lancet* 347:1779-1780
4. Coyle PK (1993) Neurologic complications of Lyme disease. *Rheum Dis Clin North Am* 19:993-1009
5. Edwards MK, Bonnin JM (1991) White matter disease. In: Atlas SW (ed) *Magnetic resonance imaging of the brain and spine*. Raven Press, New York, pp 467-499
6. Erken E (1996) Familial Mediterranean fever - a review (in Turkish). *Turk J Rheumatol* 1:19-22
7. Gökalp HZ, Başkaya MK, Aydın V (1992) Pseudotumor cerebri and familial Mediterranean fever. *Clin Neurol Neurosurg* 94:261-263
8. Harding AE, Sweeney MG, Miller DH, et al (1992) Occurrence of a multiple sclerosis like illness in women who have Leber's hereditary optic neuropathy mitochondrial DNA mutation. *Brain* 115:979-989
9. Henckes M, Roskams T, Vanneste S, Van Damme B, Vanrantghem Y (1994) Polyarteritis nodosa type vasculitis in a patient with familial Mediterranean fever treated with cyclosporine-A. *Transpl Int* 7:292-296
10. Hurst RW, Grossman RI (1994) Neuroradiology of central nervous system vasculitis. *Semin Neurol* 14:320-340
11. International Study Group for Behcet's Disease (1990) Criteria for diagnosis of Behcet's disease. *Lancet* 335:1078-1080
12. Irtman G, Öztura I, Berber N, Başoğlu M (1994) Amyloid ophthalmoplegia associated with familial Mediterranean fever (in Turkish) XXX. National Neurology Congress, 9-14 October, Adana, Turkey
13. Lossos A, Eliashiv S, Ben-Chatrit E, Reches A (1993) Optic neuritis associated with familial Mediterranean fever. *J Clin Neuroophthalmol* 13:141-143
14. Matzner Y, Brzesinski A (1994) C5a-inhibitor deficiency in peritoneal fluids from patients with familial Mediterranean fever. *N Engl J Med* 311:287-290
15. Matzner Y (1995) Biologic and clinical advances in familial Mediterranean fever. *Crit Rev Oncol Hematol* 18:197-205
16. Matzner Y (1996) Familial Mediterranean fever (letter). *Lancet* 348:554
17. McDermott EM, Drenth JPH, Powell RJ (1996) Familial Mediterranean fever (letter). *Lancet* 348:554-555
18. Meyerhoff J (1980) Familial Mediterranean fever: Report of a large family, review of literature, and discussion of the frequency of amyloidosis. *Medicine* 59:66-77
19. Moore PM, Calabrese LH (1994) Neurologic manifestation of systemic vasculitides. *Semin Neurol* 14:300-306
20. Palopoli JJ, Waxman J (1987) Colchicine neuropathy or vitamin B12 deficiency neuropathy? *N Engl J Med* 317:1290-1291
21. Poser CM, Patty DW, Scheiberg L, et al (1983) New diagnostic criteria for MS: guidelines for research protocols. *Ann Neurol* 13:227-231
22. Pras E, Aksentijevich I, Gruberg L, et al (1992) Mapping of a gene causing familial Mediterranean fever to short arm of chromosome 16. *N Engl J Med* 326:1509-1512
23. Rosenberg N (1996) The neuromythology of silicone breast implants. *Neurology* 46:308-314
24. Schwabe AD, Monroe JB (1988) Meningitis in familial Mediterranean fever. *Am J Med* 85:715-717
25. Shoat M, Danon YL, Rotter JI (1992) Familial Mediterranean fever: analysis of inheritance and current linkage data. *Am J Med Genet* 15:183-188
26. Topaloğlu R, Saatçi Ü, Bakkaloğlu A, Beşbaş N, Başsoy V (1992) Evaluation of the hypercoagulable state by measuring protein-C and antithrombin-III levels in nephrotic syndrome and in familial Mediterranean fever-related amyloidosis. *Turk J Pediatr* 34:15-20
27. Wirguin I, Podgaetski M, Frishner S, et al (1996) Stroke in young patients with familial Mediterranean fever. Meeting abstract in 3rd World Stroke Congress and 5th European Stroke Conference, Munich Germany, September 1-4 [Abstract in *Cerebrovasc Dis* 6 [Suppl 2]: 98